Oncology & Cancer

Socioeconomic disadvantage linked to breast cancer tumor disparity

Racial and ethnic disparities in breast tumor aggressiveness might be explained by social factors that influence the developing tumor and place those in disadvantaged groups at higher risk for aggressive breast cancer, according ...

Oncology & Cancer

Breast cancer recurrence defined by hormone receptor status

Human epidermal growth factor (HER2) positive breast cancers are often treated with the same therapy regardless of hormone receptor status. New research published in BioMed Central's open access journal Breast Cancer Research ...

Oncology & Cancer

Imaging agents predict breast cancer response to endocrine therapy

Research published in the July issue of The Journal of Nuclear Medicine shows imaging progesterone receptor (PR) status also may be able to identify responders and nonresponders to endocrine therapy at an early stage. Estrogen ...

Oncology & Cancer

New target, new drug in breast cancer

Many breast cancers depend on hormones including estrogen or progesterone for their survival and proliferation. Eight years of lab work at the University of Colorado Cancer Center and elsewhere suggest that the androgen (AR) ...

Oncology & Cancer

Study role testosterone may play in triple negative breast cancer

Could blocking a testosterone receptor lead to a new way to treat an aggressive form of breast cancer? That's a question researchers at Mayo Clinic in Arizona and the Translational Genomics Research Institute (TGen) are exploring. ...

page 7 from 8